Gyomor- és nyelőcsőrák: vizsgálatok itt: Norvégia
14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07405151 · EU 2026-525213-31-00 - 1/2. fázisTaking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - 1/2. fázisTaking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Lørenskog, Oslo
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Where
- Kristiansand, Lørenskog, Stavanger
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00 - 1/2. fázisTaking peopleA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00 - 1/2. fázisTaking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - 2. fázisTaking peopleTiming of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
- Where
- Oslo, Tromsø
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT07000253 - 3. fázisTaking peopleThe IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients with Peritoneal Metastasis
- Where
- Oslo, Tromsoe
- Életkor
- 18 év and over
- People
- 96 worldwide
- Run by
- Karolinska University Hospital
See details and how to join2024-514879-17-00 - 1/2. fázisTaking peopleSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Where
- Oslo
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06445972 · EU 2023-509306-29-00 - 3. fázisTaking peopleTrial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
- Where
- Bergen, Lorenskog, Oslo, Trondheim
- Életkor
- 18 év and over
- People
- 228 worldwide
- Run by
- Daiichi Sankyo Inc.
See details and how to join2024-513122-27-00 - 3. fázisTaking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Bergen, Lørenskog, Oslo, Trondheim
- Életkor
- 18 év and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - 3. fázisTaking peopleChemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
- Where
- Oslo, Tromsø, Trondheim
- Életkor
- 18 év to 80 év
- People
- 1020 worldwide
- Run by
- Karolinska University Hospital
See details and how to joinNCT04460352 - 3. fázisNot yet taking people in NorvégiaSurveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
- Where
- Oslo, Tromsø, Trondheim
- Életkor
- 18 év and over
- People
- 952 worldwide
- Run by
- University of Dublin, Trinity College
See details and how to joinNCT06115629